“Is curing patients a sustainable business model?”

No financial incentive in creating definite cures

#Health

Tue, Apr 17th, 2018 11:00 by capnasty NEWS

According to CNBC, a report by a Goldman Sachs analysts notes that gene therapy treatment could be "bad for business in the long run."

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

  387

 

You may also be interested in:

"Unlike other gene-editing methods, it is cheap, quick and easy to use."
“The Ferrari of the virus world.”
Stroke Turns Man Gay
After Success in Mice, Ant-Ageing Compound Set for Human Trials
"A way to alter any organism's DNA much like a computer user can edit a Word document."